

Indications for boost irradiation after quadrantectomy for early breast cancer

Lena Marinova, Tatiana Hadjieva

Introduction. Controversies still exist on boost irradiation after quadrantectomy for early breast cancer.

Material and methods. A retrospective study on 341 pTNM I-II staged (<3 cm) patients aimed to evaluate boost irradiation effect mainly upon local tumour control, measured by Recurrence Free Survival - (RFS) and consequently to Disease Free Survival (DFS). Whole breast, scar and chest wall were irradiated by 50 Gy telecobalttherapy in all patients and 224 of them were chosen to receive additional 10 Gy to the tumour bed.

Results and conclusion. No significant difference was registered in 10 years RFS (96%) in 224 patients receiving 10 Gy boost irradiation, compared to 95% RFS of the 117 patients irradiated with 50 Gy to the whole breast. DFS was 89% at 10th year and did not differ in both groups. The local relapse rate at 10th year was among the lowest figures reported – 3.4% for boost group and 3.6% for no-boost group. Proportional hazard Cox model reveal a high-risk group for local recurrence that might benefit from boost irradiation (tumour size 2.1-3 cm; G3, negatives steroid receptors). In our practice, patients developing such characteristics have indications for boost irradiation.

Radioterapia u chorych z wczesnym rakiem sutka po kwadrantektomii – wskazania do podwyższenia dawki na wydzielone pole („boost”)

Wstęp. Istnieją kontrowersje dotyczące stosowania podwyższonej dawki na wydzielone pole („boost”) u chorych po kwadrantektomii, wykonanej we wczesnym raku sutka.

Materiał i metody. Przeprowadzono retrospektywną analizę 341 chorych z rakiem sutka w stadium pTNM I/II (guz poniżej 3 cm średnicy) po kwadrantektomii pod kątem oceny stosowania podwyższonej dawki na wydzielone pole („boost”) w celu zapewnienia kontroli miejscowej, mierzonej jako czas przeżycia bez wznowy (Recurrence Free Survival, RFS) i w efekcie, czas przeżycia bez choroby (Disease Free Survival, DFS). Podawano dawkę 50 Gy (techniką teleradioterapii kobaltowej) na całą pierś, bliżną pooperacyjną i ścianę klatki piersiowej, a u 224 chorych dodatkowo „boost” 10 Gy, skierowany na łóżę po guzie.

Wyniki i wnioski. W ciągu 10 lat obserwacji nie stwierdzono statystycznie znamiennej różnicy w zakresie odsetka RFS: 96% w grupie 224 chorych, które otrzymały „boost” i 95% w grupie 117 chorych, które nie otrzymały „boostu”. Odsetek DFS był w 10-tym roku obserwacji taki sam w obu grupach – tj. 89%. Odsetek wznów miejscowych po 10 latach należał do najniższych opisywanych w literaturze – 3,4% w grupie, która otrzymała „boost” i 3,6% chorych w grupie, która nie otrzymała „boostu”. Analiza wieloczynnikowa metodą Coxa pozwoliła wyłonić grupę chorych o podwyższonym ryzyku wznowy miejscowej, które mogłyby odnieść wyraźną korzyść z naświetlania, z zastosowaniem podwyższonej dawki na wydzielone pole. Są to chore, u których rozmiary guza osiągają 2,1-3 cm, nowotwór zaś wykazuje cechę G3 i nie posiada receptorów steroidowych.

Key words: early breast cancer, quadrantectomy, boost irradiation

Słowa kluczowe: wczesny rak sutka, kwadrantektomia, napromienianie z podwyższeniem dawki na wydzielone pole

Introduction

It is a standard practice to recommend radiotherapy (RT) to residual breast after breast conserving surgery (BCS). Recurrence rate at the remaining breast near to

the tumour after BCS ranges between 43-9% without radiotherapy [1-5]. The difference depends on structure of evaluated subgroups and different term of the follow-up.

Now, data from seven randomized trials have shown a substantial improvement in local tumour control in irradiated patients after BCS compared to non-irradiated on average from 27% to 7% at 10 years [6-7]. Moreover, there is a well-established practice in most European countries and in US to give an additional dose as a "boost" to the tumour area. The rationale for such increase of

Department of Radiation Oncology, UH "Queen Giovanna"
Medical University, Sofia, Bulgaria

The study was presented at the Second Conference
"Diagnosis and treatment of breast cancer" Warsaw, 22-24 May 2001




Figure 1. Recurrence Free Survival of patients with early breast cancer after quadrantectomy and radiotherapy for boost and no-boost group




Figure 2. Recurrence Free Survival in boost and no-boost group, with tumour size between 2.1 and 3.0 cm (pT2)




Figure 3. Recurrence Free Survival in pT2 (2.1-3.0 cm) and G3 boost and no-boost group




Figure 4. Disease Free Survival of patients with early breast cancer after quadrantectomy and radiotherapy for boost and no-boost group

Disease free survival (DFS)

Two of the recurred patients developed pulmonary and hepatic distant metastases and later succumbed. They belong to each of the compared groups. DFS is presented on Figure 4. Again, no difference in DFS was detected in two investigated patients groups reaching 89% at 10th years.

Discussion

Our study include a substantial number of patients: 117 cases whose remaining breast was irradiated up to TD 50 Gy and 224 patients with additional 10 Gy boost irradiation. Both groups were balanced according to patient, tumour and treatment characteristics (Table I).

Table I. Patients, tumour and treatment characteristics in both groups

Parameters	Boost group		No-boost group		P
	N	%	N	%	
All	224	65.7	117	34.3	
Age (years)					
>30	4	18	1	1.0	0.82
31-40	23	10.3	25	21.4	0.19
41-50	81	36.0	34	29.0	0.26
51-60	65	29.0	32	27.4	0.84
<60	51	22.8	25	21.4	0.92
Histology					
Invasive ductal	174	77.7	94	80.3	0.7
Invasive lobular	27	12.0	14	12.0	1.0
Others	23	10.3	9	7.7	0.8
High risk parameters					
pT2/(2.1-3 cm)	39	17.5	31	26.5	0.36
G3	35	15.6	15	12.8	0.78
Microcalcificates	11	5.0	4	3.4	0.93
Comedo structures	7	3.0	4	3.4	0.93
Lymph vessel invasion	2	1.0	2	1.7	0.95
Venous vessel invasion	5	2.2	1	1.0	0.91
Tumour necrosis	6	2.7	0	0	0.39
Tumour metaplasia	3	1.3	0	0	
EIDC <i>in situ ductale</i>	2	1	1	1	
EIDC <i>in situ lobulare</i>	4	1.8	1	1	
Steroid receptors negative	56	25.0	18	15.4	0.38
Hormonal therapy	160	72.0	81	70.0	0.74
Adjuvant chemotherapy	68	30.0	23	20.0	0.35

The 10-survival analysis demonstrates significant difference neither in RFS nor in DFS between boost and no-boost arms. Our 10-years long-term results reveal the good level of Bulgarian oncological practice in early breast cancer ranking them among the best survival results (96-95% RFS and 89% DFS) [5, 6].

The numbers of observation event in our study – 12 cases with local relapses after radiotherapy – were too small to prove any difference, if it exists. Only 4 out of 117 patients, receiving 50 Gy developed local recurrences. Similarly, 8 out of 224 patients showed local relapse despite of 60 Gy administered by telecobalttherapy. Zissiadis and al. [15] reported no influence on LTC at 5 years in 78% of his patients treated by quadrantectomy and additional boost irradiation. Similar conclusion was made in NSABP-06 trial [16]. Only

8% of local relapses were registered at 5 years without boost irradiation.

Later, two large randomised trials investigated the benefit after boost irradiation. The results from Lion trial, France, were based on 1024 patients treated by lumpectomy with negative margins and 50 Gy tangential radiation to the whole breast, randomised to either 10 Gy boost or no further RT. The relative risk for local recurrence at the 5th year was higher in the no-boost arm (4.5% compare to 3.6%) ($p < 0.044$) and the authors advocate the benefit of boost irradiation in case of negative margins [17].

The EORTC boost trial increased the cohort and includes 5318 patients to prove or disprove the benefit from 16 Gy boost irradiation after lumpectomy with negative margins [18, 19]. The absolute benefit was 2.5% at the 5th years with a significant decrease of local recurrences from 6.8% in the no-boost arm compared to 4.3% in the boost arm ($p < 0.0001$). In younger patients boost RT showed higher advantage for LTC than in the patients over 50 years of age. EORTC trial concludes that boost irradiation is essential in case of unclear or positive margins after lumpectomy.

The EORTC boost trial increased the cohort and includes 5318 patients to prove or disprove the benefit from 16 Gy boost irradiation after lumpectomy with negative margins [18, 19]. The absolute benefit was 2.5% at the 5th years with a significant decrease of local recurrences from 6.8% in the no-boost arm compared to 4.3% in the boost arm ($p < 0.0001$). Boost RT shows higher advantage in younger patients than in the patients over 50 years of age. EORTC trial concludes that boost irradiation is essential in case of unclear or positive margins after lumpectomy.

We could not investigate the relation between surgical margins and boost irradiation. A clear evidence of margins status could not be found in the operative protocols of all patients. In a number of them, the information was lacking, because evaluating procedure of surgical margins still is not a routine practice in some Bulgarian hospitals. In some cases, the precise information about volume of excised breast was also missing. So, the margin status of our patients could be addressed as unknown, as cited in many publications

Trying to overcome the disadvantage of the low numbers of events, we performed a regression analysis by proportional multivariate hazard Cox model. We analyzed the influence of several prognostic parameters (PP) on RFS in each group: tumour size 2.1-3 cm versus smaller size, degree of differentiation (G3 versus G1 plus G2), volume of axillary clearance (under and over seven negative lymph nodes) and tumour steroid receptors status (positive versus negative) (Table III).

PP as bigger tumour size ($p = 0.0125$), G3 (0.0001), negative steroid receptors (0.0068) have a negative influence on RFS of non-boost arm.

The boost irradiation overcome the above registered negative influence of bigger pT, G3 and negative hormonal receptors on local RFS (Table III).

Proportional Cox regression analysis did not reveal influence of other parameters as negative prognostic

Table III. Influence of boost irradiation on Recurrence – Free Survival related to four tumour parameters.
The analysis was performed by Proportional Hazard Cox model

Parameter	Chi ²	df	p value
RFS in patients without boost irradiation	Chi ² 55.5	df=4	p=0.00001
Variables	β		
Tumour size (2.1-3 cm)	-0.23		p= 0.01
Volume of axillary dissection	-0.02		p=0.06
Degree of differentiation (G)	-0.83		p=0.00
Positive steroid receptors	-0.15		p=0.006
RFS in patients with boost irradiation	Chi ² 2.7	df=4	p=0.59
Variables	β		
Tumour size (2.1-3 cm)	-0.05		p=0.70
Volume of axillary dissection	-0.01		p=0.23
Degree of differentiation (G)	-0.21		p=0.29
Positive steroid receptors	-0.02		p=0.73

factors for local recurrence in both groups: microcalcifications, tumour necrosis, vessel invasion, tumour metaplasia, extensive intraductal component (EICD), comedo structures

Our study does not pretend for final conclusive results. The figures of 3.4-3.6% local recurrence rate in both evaluated groups are among the lowest data cited in the literature. It might be a result of wider surgery with negative margins. Simultaneously, we achieved good cosmetic results in boost group that has been reported elsewhere [20].

The long term survival with equivalent evaluation of cosmetic results will reveal further information concerning ultimate local control rate as well as ultimate survival in relation to higher dose postoperative RT in BCS [21].

Conclusions

1. There was no significant difference registered in 10 years RFS (96%) in patients receiving 10 Gy boost irradiation, compared to 95% RFS of the patients irradiated by 50 Gy to the whole breast.
2. DFS was 89% at 10th year in the cohort of 341 patients after BCS in early breast cancer (pT<3 cm)
3. The relapse rate at 10th year was among the lowest figures reported – 3.4% for boost group and 3.6% for no-boost group.
4. Proportional hazard Cox model reveal a high-risk group for local recurrence that might benefited from boost irradiation after quadrantectomy with unknown surgical margin (tumour size 2.1-3 cm, G3, negative steroid receptors).

Lena Marinova MD, PhD
Assistant Professor
Department of Radiation Oncology
UH "Queen Giovanna
8, Bjalo More str.
Sofia 1527, Bulgaria
e-mail: rad@cserve.mgu.bg

References

1. Fisher B, Redmond C, Poisson R et al. Eight-years result in randomised clinical trial comparing mastectomy and lumpectomy with or without radiation in the treatment of breast cancer. *New Engl J Med* 1989; 320: 822-8.
2. Fisher B, Anderson S, Redmond C et al. Reanalysis and results after 12 years of follow-up in randomised clinic trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. *N Engl J Med* 1995; 333: 1456-61.
3. Liljegren G, Holmberg L, Amadi HO et al. Sector resection with or without postoperative radiotherapy for Stage I breast cancer: five year results of randomized trial. *J Natl Cancer Inst* 1994; 86: 717-22.
4. Clark RM, Mc Culloch PB, Levine M et al. Randomised clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. *J Natl Cancer Inst* 1992; 84: 683-9.
5. Veronesi U, Luini A, del Vecchio M et al. Radiotherapy after breast preserving surgery in women with localized cancer of the breast. *N Engl J Med* 1993; 328: 1587-91.
6. Early Breast Cancer Trialists/Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. *N Engl J Med* 1995; 333: 1444-55.
7. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. *Lancet* 2000; 355: 1757-70.
8. Timothy AR, Overgaard J, Overgaard M et al. Treatment of early carcinoma of the breast. *Lancet* 1979; 2: 25-6.
9. Holland R, Veling SH, Mravunac M et al. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. *Cancer* 1985; 56: 979-90.
10. Holmberg L. Breast conserving surgery without radiotherapy. *Acta Oncol* 1995; 34: 681-3.
11. Jacobson JA, Danforth DN, Cowan KH et al. Ten- years results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. *N Engl J Med* 1995; 332: 907-11.
12. Kasumi F, Iwase T, Yoshimoto M et al. Experience of quadrantectomy with axillary dissection without radiotherapy subtended by serial pathological examination for stage I breast cancer. *J Cancer Res Clin Oncol* 1995; 121: 549-54.
13. Lichter AS, Lippman ME, Danforth D Jr et al. Mastectomy versus breast conserving therapy in the treatment stage I and II. Carcinoma of the breast: a randomised trial at the National Cancer Institute. *J Clin Oncol* 1992; 10: 976-83.
14. Stat soft, Inc. Statistica for Windows. Computer Program Manual, 1995. Tulsa OK, USA.
15. Zissiadis Y, Langlands AO, Barraclough B, Boyages J. Breast conservation: long term results from Westmead Hospital. *Aust NZ J Surg* 1997; 67-71.
16. Fisher B, Anderson S, Redmond C et al. Reanalysis and results after 12 years of follow-up in randomised clinic trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. *N Engl J Med* 1995; 333: 1456-61.
17. Romestaing P, Lehingue Y, Carrie C et al. Role of a 10 Gy boost in the conservative treatment of early breast cancer: results of a randomised clinical trial in Lyon, France. *J Clin Oncol* 1997; 15: 963-68.
18. EORTC. Phase III study in the conservative management of breast carcinoma by tumorectomy and radiotherapy: assessment of the role of a booster dose of radiotherapy. Protocol 22881/ 10882,1989.
19. Colette L, Fourquet, Horiot JC et al. Impact of boost dose of 16 Gy on local control in patients with early breast cancer: the EORTC "Boost versus no boost" trial. *Radiother Oncol* 2001; 56 suppl I: S46.
20. Marinova L, G Todorov, Koleva I et al. Cosmetic results after conservative surgery and radiotherapy of patients with early breast cancer. *Journal of BUON*. 1998; 3: 39-44.
21. Overgaard M. Radiotherapy as a part of multidisciplinary treatment strategy in early breast cancer. *Eur J Cancer* 2001; 37 suppl 7: 33-43.

Paper received: 20 August 2002

Accepted: 8 October 2002